How Is Aera Therapeutics CEO Akin Akinc Building a Biotech Company and Breaking Barriers in Genomic Medicine?

July 19, 2023
by
GV (Google Ventures)
YouTube video player
How Is Aera Therapeutics CEO Akin Akinc Building a Biotech Company and Breaking Barriers in Genomic Medicine?

TL;DR

Aera Therapeutics is developing protein nanoparticles to address the delivery barriers limiting genetic medicines. After a financing of 193 million dollars, CEO Akin Akinc describes why compelling science, an important delivery problem, a world-class scientific founder, experienced board members and long-term investors convinced him to join the company. Read on to understand the technology, leadership and ambitions behind Aera.

Transcript

GV has had a clear vision and Mission to support Innovative Founders to make a real impact in the world particularly on the life science team we're here to make an impact on patients lives and we're just so thrilled to have error Therapeutics as part of our portfolio era has recently come off a financing of 193 million dollars and we're thrilled to... Read More

Key Insights

  • đź’˘ Era Therapeutics' recent financing of $193 million highlights its potential in the genetic medicine sector.
  • 🏂 Akin Akinch's personal journey and the involvement of renowned investors and board members have enhanced Era's credibility and growth prospects.
  • đźšš The development of protein nanoparticles as a delivery solution could revolutionize the field of genetic medicines by addressing existing limitations and expanding treatable tissues.
  • 🥹 The future of genetic medicine holds promise for personalized treatments, targeted insertion technologies, and easier administration methods.

Explore YouTube Video Summarizer or Get YouTube Transcript Extractor

Questions & Answers

Q: What problem is Aera Therapeutics trying to solve?

Aera Therapeutics is working on the delivery of genetic medicines to the right tissues in patients. Akin Akinc says delivery technologies have not advanced as quickly as therapeutic modalities, limiting the broader application of genetic medicines.

Q: What is at the core of Aera Therapeutics' technology?

Aera is developing protein nanoparticles as a new strategy for delivering genetic medicines. The company aims to add another approach to a field currently relying on options such as viral delivery technologies, lipid nanoparticles and small conjugates.

Q: Why did Akin Akinc join Aera Therapeutics?

Akinc saw an opportunity to work on the important problem of genetic medicine delivery using compelling science and a new delivery approach. He was also drawn to the world-class scientific founder, experienced board members and investors committed to building a lasting, impactful company.

Q: How did Akin Akinc first connect with Aera Therapeutics?

The Broad Institute of MIT and Harvard contacted Akinc by email, but the message initially went into his spam folder. He found it later that week, held an initial meeting and became increasingly convinced that the opportunity was too exciting to pass up.

Q: How much financing did Aera Therapeutics secure?

Aera Therapeutics had recently completed a financing of 193 million dollars. GV described the company as part of its portfolio and expressed enthusiasm about supporting its work.

Q: Why does Aera Therapeutics believe more genetic medicine delivery strategies are needed?

Existing solutions include viral delivery technologies, lipid nanoparticles, GalNAc and other small conjugates for payloads such as antisense oligonucleotides and siRNAs, plus some work on extracellular vesicles. Akinc argues that one approach is unlikely to work for every genetic medicine technology.

Q: How does Akin Akinc work with Aera's scientific founder, Feng Zhang?

Akinc describes Feng Zhang as brilliant, productive, humble and kind, with a strong sense of where science is heading. Akinc consults him about scientific developments and pays attention both when Zhang is excited and when he is not.

Q: How does Aera's board support Akin Akinc as a first-time CEO?

Akinc values working with investors and board members who have successfully built and run companies. He says their experience is critically important because he respects them and can learn from them while growing into the CEO role.

Summary & Key Takeaways

  • Definition: Aera Therapeutics is pursuing protein nanoparticles as a new approach to delivering genetic medicines.

  • Number: Aera Therapeutics recently completed a financing of 193 million dollars.

  • Who: Akin Akinc is Aera Therapeutics' CEO and describes himself as a first-time CEO.

  • Step 1: The Broad Institute of MIT and Harvard contacted Akinc by email, which initially entered his spam folder.

  • Step 2: Akinc found the email later that week and attended an initial meeting to learn more.

  • Step 3: Compelling science, an important delivery problem and experienced people convinced Akinc to join Aera.

  • Compare: Genetic medicine modalities advanced rapidly, while delivery technologies did not keep pace and limited broader applications.

  • Tool: Current delivery options include viral technologies, lipid nanoparticles, GalNAc, small conjugates and some extracellular vesicle work.

  • Who: GV and ARCH were lead investors committed to building an impactful company for the long term.

  • Who: Board participants mentioned include John Maraganore, David, Vicki Sato, Bob Nelson, Izzy and Josh Wolfe from Lux.

  • Who: Akinc values Feng Zhang's scientific judgment, humility and kindness when assessing emerging areas of science.


Read in Other Languages (beta)

Share This Summary 📚

Explore More Summaries from GV (Google Ventures) 📚